CN114144431A - 人源化抗TNFα抗体及其用途 - Google Patents

人源化抗TNFα抗体及其用途 Download PDF

Info

Publication number
CN114144431A
CN114144431A CN202080052415.7A CN202080052415A CN114144431A CN 114144431 A CN114144431 A CN 114144431A CN 202080052415 A CN202080052415 A CN 202080052415A CN 114144431 A CN114144431 A CN 114144431A
Authority
CN
China
Prior art keywords
tnf
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080052415.7A
Other languages
English (en)
Other versions
CN114144431B (zh
Inventor
谢良志
孙春昀
汪瑞
杨少君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinocelltech Ltd
Original Assignee
Sinocelltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinocelltech Ltd filed Critical Sinocelltech Ltd
Publication of CN114144431A publication Critical patent/CN114144431A/zh
Application granted granted Critical
Publication of CN114144431B publication Critical patent/CN114144431B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供结合TNFα的人源化单克隆抗体、编码所述抗体的核酸序列(包括重/轻链可变区)、含有所述核酸序列的载体、药物组合物和试剂盒。单克隆抗体能够在特异性地结合分泌型TNFα蛋白的同时保留ADCC活性及较弱的CDC活性、阻断TNFα与受体TNFR I、TNFR II的结合，但对细胞膜表面的膜型TNFα蛋白仅有微弱的结合。在小鼠类风湿关节炎模型中，单克隆抗体可有效降低关节炎评分。在食蟹猴单次给药药代中，单克隆抗体在体内维持较长时间的药物暴露，衰减速度慢。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080052415.7A 2019-08-08 2020-08-06 人源化抗TNFα抗体及其用途 Active CN114144431B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910731669 2019-08-08
CN2019107316690 2019-08-08
PCT/CN2020/107481 WO2021023274A1 (zh) 2019-08-08 2020-08-06 人源化抗TNFα抗体及其用途

Publications (2)

Publication Number Publication Date
CN114144431A true CN114144431A (zh) 2022-03-04
CN114144431B CN114144431B (zh) 2023-04-14

Family

ID=74502678

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052415.7A Active CN114144431B (zh) 2019-08-08 2020-08-06 人源化抗TNFα抗体及其用途

Country Status (2)

Country Link
CN (1) CN114144431B (zh)
WO (1) WO2021023274A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117783524A (zh) * 2024-02-26 2024-03-29 中国医学科学院医学生物学研究所 一种双抗体夹心法间接定量检测柯萨奇a10型病毒抗原的建立与应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819575B (zh) * 2022-08-24 2023-06-27 武汉爱博泰克生物科技有限公司 针对人肿瘤坏死因子-α的单克隆抗体
CN117894366A (zh) * 2024-01-19 2024-04-16 南京京达生物技术有限公司 基于计算模拟筛选抗体的方法及所得抗体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216293A1 (en) * 2005-03-24 2006-09-28 Couto Fernando J R TNFalpha-neutralizing antibodies
WO2008144753A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
CN102037012A (zh) * 2008-04-23 2011-04-27 宜康公司 抗-TNFα抗体
CN104892760A (zh) * 2014-03-04 2015-09-09 北京安保康生物医药科技有限公司 抗TNFα的全人源单克隆抗体及其应用
CN108368168A (zh) * 2015-12-18 2018-08-03 Ucb生物制药私人有限公司 结合TNFα的抗体分子

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216293A1 (en) * 2005-03-24 2006-09-28 Couto Fernando J R TNFalpha-neutralizing antibodies
WO2008144753A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
CN102037012A (zh) * 2008-04-23 2011-04-27 宜康公司 抗-TNFα抗体
CN104892760A (zh) * 2014-03-04 2015-09-09 北京安保康生物医药科技有限公司 抗TNFα的全人源单克隆抗体及其应用
CN108368168A (zh) * 2015-12-18 2018-08-03 Ucb生物制药私人有限公司 结合TNFα的抗体分子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MACHOLD，K.P. ET AL.: "Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease.", 《EXPERT OPINION ON BIOLOGICAL THERAPY.》 *
杨涛: "利用噬菌体表面展示技术制备抗人肿瘤坏死因子α单链抗体及其人源化改造", 《中国博士学位论文全文数据库（电子期刊）医药卫生科技辑》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117783524A (zh) * 2024-02-26 2024-03-29 中国医学科学院医学生物学研究所 一种双抗体夹心法间接定量检测柯萨奇a10型病毒抗原的建立与应用
CN117783524B (zh) * 2024-02-26 2024-05-03 中国医学科学院医学生物学研究所 一种双抗体夹心法间接定量检测柯萨奇a10型病毒抗原的建立与应用

Also Published As

Publication number Publication date
CN114144431B (zh) 2023-04-14
WO2021023274A1 (zh) 2021-02-11

Similar Documents

Publication Publication Date Title
CN111171150B (zh) 抗人tslp抗体及其用途
JP6867955B2 (ja) 抗ｏｘ４０抗体及びその使用方法
CN109651507B (zh) 一种激动型4-1bb单克隆抗体
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
JP7215759B2 (ja) ４－１ｂｂ抗体およびその製造方法と使用
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
CN114144431B (zh) 人源化抗TNFα抗体及其用途
CN112513090B (zh) 结合人il-4r的抗体、其抗原结合片段及其医药用途
US20220363781A1 (en) Anti-tslp antibody and uses thereof
MX2011001909A (es) Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos.
CN113501878B (zh) 针对人tslp的多种抗体及其用途
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
US20160159922A1 (en) Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis
CN114127106B (zh) 人源化抗VEGF Fab抗体片段及其用途
CN114286827B (zh) 人源化抗il17a抗体及其应用
KR20190126769A (ko) 항-il-5 항체
CN114008075A (zh) 人源化抗vegf单克隆抗体
EP2821416B1 (en) Novel anti-human il-23 receptor antibody
CA3237268A1 (en) Human tumor necrosis factor alpha antibodies
CN112521499B (zh) 抗cxcl13抗体及其用途
US20240228605A9 (en) Antibodies against human tslp and use thereof
CN116715769B (zh) 抗hvem抗体、制备方法及其用途
WO2023030311A1 (zh) 靶向Siglec15的抗原结合蛋白及其用途
WO2023125289A1 (zh) 抗pd-1抗体及其用途
CN115947855A (zh) 抗cd24抗体的制备及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066236

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant